Indonesia and Germany join forces to save biodiversity
Business Announcement
Berlin, Germany; 19.05.2022 — Today, the Indonesian “Institut Pertanian Bogor University (IPB University)” and the German “Leibniz Institute for Zoo and Wildlife Research (Leibniz-IZW)” signed a memorandum of understanding (MOU) witnessed by the Indonesian Ambassador, the representative of the Directorate General of Nature Conservation and Ecosystem Ministry of Environment and Forestry of the Republic of Indonesia and the Director of the German Zoo Leipzig. The MOU is outlining a new collaborative strategy for advancing future scientific and educational solutions to local and global sustainability and biodiversity conservation challenges.
Novateur Ventures, a leading global life sciences advisory firm, announced it has participated in the $13.6M (£10.3M) seed investment raised by Epitopea, a cancer therapeutics company recently spun out of the Université de Montréal (UdeM) / IRIC in partnership with IRICoR. This investment will support the further development and application of Epitopea’s ground-breaking approaches to identify shared, aberrantly expressed tumor-specific antigens (TSA), that Epitopea has exclusively licensed from UdeM.
A consortium led by international scientists from the non-profit, open-science COVID Moonshot has been awarded an initial $68,662,387 from the US National Institutes of Health (NIH) to discover and develop globally accessible and affordable novel oral antivirals to combat COVID-19 and future pandemics.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded approximately $577 million to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.
AWS joins Q-NEXT as an institutional partner. Q-NEXT is a DOE National QIS Research Center led by Argonne.
The US Department of Energy (DOE) is joining the Frontier Development Lab (FDL) program to advance basic research at the agency. FDL is a public-private partnership between the SETI Institute, NASA, USGS, Google Cloud, Intel, Lockheed Martin, Nvidia, Trillium Technologies and other US and international partners.
Health research enabled by partnership between the University of Leicester and both the University Hospitals of Leicester NHS Trust and Leicestershire Partnership NHS Trust has been recognised among the best in the UK.
Building on momentum from the highly successful COVID-19 vaccine clinical trials, the HIV Vaccine Trials Network (HVTN) is launching a new HIV awareness campaign and unveiling a first-of-its-kind national registry that will provide updated HIV information and make it easier to learn about and participate in HIV clinical trials at HelpEndHIV.org.
To meet the demands of Singapore’s cybersecurity evaluation needs, Nanyang Technological University, Singapore (NTU Singapore) and the Cyber Security Agency of Singapore (CSA) officially launched the National Integrated Centre for Evaluation (NiCE) today. The first of its kind in South-East Asia, the joint centre serves as a one-stop facility for cyber security evaluation and certification. NiCE is a unique initiative that pools industrial and research expertise together to develop a sustainable academia-industry-government ecosystem for product evaluation and certification in Singapore. The centre also aims to help build a pipeline of local product evaluation talent, which will maximise economic opportunities and boost Singapore’s branding as a cybersecurity hub. Located on the NTU Smart Campus, NiCE was officially launched today by Minister for Communications and Information and Minister-in-charge of Smart Nation and Cybersecurity, Mrs Josephine Teo.
Children’s Hospital Colorado is the first hospital in the world to implant the newly FDA-approved G-Armor Stent. Although the stent is designed to be used in the smallest of patients, it was first implanted in a Colorado father of two. The stent was developed by interventional cardiologist, Gareth Morgan, MD, who oversees the Interventional Congenital Cardiology program at Children’s Colorado in conjunction with NuMed for Children.
The Spanish research community’s growing commitment to open access publishing has been bolstered by the announcement of a new agreement between the Consortium of Catalan University Services (Consorci de Serveis Universitaris de Catalunya, CSUC) and gold open access publisher Frontiers.
Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, and City of Hope, one of the largest cancer research and treatment organizations in the United States, today announced that the first patient was dosed in a Phase 1 clinical trial evaluating the safety of novel cancer-killing virus CF33-hNIS VAXINIA when used in people with advanced solid tumors. The City of Hope-developed oncolytic virus has been shown to shrink colon, lung, breast, ovarian and pancreatic cancer tumors in preclinical laboratory and animal models.